Clinical trial
A Phase I/II Trial of Rucaparib in Combination With Ramucirumab With or Without Nivolumab in Previously Treated Patients With Advanced Gastric and Esophageal Adenocarcinoma (RiME)
NCT03995017 is registered in ClinicalTrials.gov with University of Kansas Medical Center as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase I/II Trial of Rucaparib in Combination With Ramucirumab With or Without Nivolumab in Previously Treated Patients With Advanced Gastric and Esophageal Adenocarcinoma (RiME)
- Lead sponsor
- University of Kansas Medical Center
- Phase
- Phase 1/2
- Overall status
- Unknown status
- Start date
- January 9, 2020
- Completion date
- December 31, 2024
- Enrollment
- 34 (actual)
- Sites
- 8
Conditions
As the registry lists them; a condition with its own page is linked.
esophagus cancer, adenocarcinoma, stomach cancer, adenocarcinoma